ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Iktos – AI for New Drug Design"
Episode Synopsis
Focusing on the use of AI in drug discovery, Nick is joined by Quentin Perron; CSO of Iktos. Iktos are a French biotech for ligand-based and structure-based de novo drug design focusing on multi-parametric optimization.
Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA, he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialising in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.
Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA, he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialising in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.
More episodes of the podcast For People with Purpose by SciPro
Brainomix, the Return with Eric Greveson
29/11/2024
In God we trust